🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "major milestone" in the effort against superbug strains of the bacteria, according to health experts.

An International Health Concern

Cases of gonorrhoea are escalating around the world, with figures suggesting over 82 million infections per year. Notably increased rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune step in the reality of growing infection rates, escalating drug resistance and the very limited treatment choices at this time.”

Health officials are increasingly worried about the rise in drug-resistant strains. The World Health Organization has listed it as a "high-priority threat". Ongoing monitoring showed that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Therapies Receive Clearance

Zoliflodacin, also known as a brand name, was cleared by the American regulatory agency in December for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers believe that focused deployment of this new drug will help hinder the development of resistance.

Gepotidacin, created by the pharmaceutical company GSK, also received approval in the same week. This medication, which is additionally indicated for UTIs, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a innovative non-profit model for drug creation. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This authorization signifies a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Testing Results and Worldwide Availability

Based on data detailed in a prominent scientific publication, the new drug successfully treated over nine in ten of cases of the STI. This puts it on an equal footing with the existing first-line therapy, which uses an injection and a pill. The study included nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the authority to license and sell the drug in numerous low-income and middle-income countries.

Doctors directly involved have shared optimism. The availability of a single-dose, oral treatment such as this is described as a "critical tool" for public health efforts. This is viewed as vital to reduce the burden of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea around the world.